Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

471
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
471
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

438
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
438
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

426
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
426

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concomitant Intracardiac Shunt and Venous Collaterals After Fontan Procedure: A Case Report of Percutaneous Management.

Journal of cardiovascular development and disease·2026
Same author

Percutaneous repair following massive perforation of the right coronary artery with stent deployment toward the pericardium.

Coronary artery disease·2026
Same author

A Rare Presentation of Infective Endocarditis Complicating Severe Aortic Valve Stenosis.

Journal of cardiovascular development and disease·2026
Same author

Unexpected Findings in Diffuse ST-Segment Depression and aVR ST-Segment Elevation.

Diagnostics (Basel, Switzerland)·2026
Same author

Are Coronary Calcium-Modifying Techniques Levelling the Playfield?

Medicina (Kaunas, Lithuania)·2026
Same author

Conservative Management of Iatrogenic Type a Aortic Dissection Occurring During Percutaneous Coronary Intervention.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same journal

Patients' Perspectives on Personalized Glycemic Targets for Coronary Artery Disease Prevention Based on the Haptoglobin Phenotype: A Qualitative Study.

CJC open·2026
Same journal

Initial Cardiovascular Disease Risk Assessment in Nonclinical Settings: Framingham-Simplified Model Predictive Performance in a Canadian Cohort.

CJC open·2026
Same journal

Cognition in Chronic Heart Failure: Advancing Knowledge for Better Prevention Through Remote Assessment.

CJC open·2026
Same journal

The Path Less Traveled: Embracing the Arts in Scientific Communications.

CJC open·2026
Same journal

Implementation of Integrated Behavioural Health in Outpatient Cardiology Care for Patients with Injection Drug Use-Associated Infective Endocarditis.

CJC open·2026
Same journal

Current Practice Patterns and Barriers to Intravascular Imaging-Guided Percutaneous Interventions: Insights from a Canadian Nationwide Survey.

CJC open·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K

Risk Factors and Markers for Flecainide Toxicity in Clinical Practice.

Karim Khadir1, Georgiana Pintea Bentea1, Thomas Nguyen1

  • 1Department of Cardiology, CHU Brugmann, Brussels, Belgium.

CJC Open
|January 16, 2026
PubMed
Summary
This summary is machine-generated.

Flecainide toxicity, though concerning, is linked to metabolic issues and specific heart rhythm markers, not traditional heart disease factors. Identifying these risk factors is key to safer patient management.

Keywords:
Flecainideflecainide toxicityrisk factors

More Related Videos

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.5K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.9K

Related Experiment Videos

Last Updated: Jan 18, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.5K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.9K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Flecainide is a crucial antiarrhythmic for ventricular and supraventricular arrhythmias.
  • Its clinical utility is hampered by potential severe toxicity.
  • Understanding current toxicity patterns, risk factors, and markers is essential.

Purpose of the Study:

  • To characterize flecainide toxicity in contemporary clinical practice.
  • To identify associated risk factors and predictive markers for flecainide toxicity.

Main Methods:

  • Retrospective, single-centre analysis of 300 patients receiving flecainide (2014-2022).
  • Minimum 3-month follow-up period.
  • Comparison of baseline characteristics between patients with and without flecainide toxicity.

Main Results:

  • 13% of patients (39/300) developed flecainide toxicity, with an 18% mortality rate.
  • Risk factors included sinus bradycardia, chronic kidney disease, hepatic cirrhosis, drug interactions, and specific ECG/echocardiogram findings during treatment.
  • Baseline ischemic or structural heart disease was not a significant risk factor.

Conclusions:

  • Flecainide toxicity contributes significantly to patient morbidity and mortality.
  • Metabolic factors (CKD, cirrhosis, drug interactions) and preclinical markers (bradycardia, LVEF, QT/QRS intervals) are key predictors.
  • Traditional contraindications like LV dysfunction are not primary risk factors for flecainide toxicity.